Abstract
We have developed a stable growth factor protein that is a promising candidate for a radioprotective drug suitable for treating biological damage caused by high-dose radiation. This stable growth factor, designated FGFC (fibroblast growth factor chimeric protein), demonstrates several advantages over existing drugs. Once approved, it can be stockpiled for radioprotection. We aim to develop this protein into a drug at the highest possible level achievable at a basic research institute.